Delcath Systems

Delcath Systems, Inc., based in Queensbury, New York, is a specialty pharmaceutical and medical device company focused on developing percutaneous perfusion technologies for targeted high-dose chemotherapy. The company's core mission is to revolutionize the treatment of liver cancer through its innovative Percutaneous Hepatic Perfusion (PHP) system, which is currently in Phase II and Phase III clinical trials. Delcath holds an intellectual property portfolio of 28 patents worldwide, underscoring its commitment to advancing cancer treatment.

Delcath Systems has made significant strides in the medical field, particularly in the targeted administration of chemotherapeutic agents. The company's PHP system aims to improve outcomes for patients with liver cancer by delivering high-dose chemotherapy directly to the liver, minimizing systemic exposure and associated side effects. As a publicly traded company on NASDAQ under the ticker DCTH, Delcath continues to attract attention from investors and stakeholders dedicated to innovative cancer therapies.